Quantcast

Latest Prasugrel Stories

2008-09-01 12:00:04

Eli Lilly and Company has announced encouraging results from a sub-group analysis of the Triton-TIMI 38 trial, which showed that patients who were diabetic and diagnosed with acute coronary syndromes were 40% less likely to suffer a heart attack if they were treated with prasugrel compared to clopidogrel. In addition, according to this same analysis, the combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke was reduced by 30% in diabetes patients treated with...

2008-08-31 09:00:14

MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were diabetic and diagnosed with acute coronary syndromes (ACS) were 40 percent less likely to suffer a heart attack if they were treated with prasugrel vs. clopidogrel, according to a sub-group analysis of the TRITON-TIMI 38 trial (8.2 percent vs. 13.2 percent, P The diabetic sub-group analysis was presented today by Stephen Wiviott, M.D., Assistant Professor of Medicine at Harvard Medical School and investigator with the...

2008-08-25 03:00:43

By Anonymous If Eli Lilly and Co. wins approval for its highly anticipated blood thinner, it could spark a bit of a family feud with Bristol- Myers Squibb Co., the maker of a competing drug. There are some signs it already is. Indianapolis-based Lilly has compared its drug prasugrel head-to- head with New York-based Bristol-Myers' Plavix, the current leading blood thinner. Co-marketed with France-based Sanofi-Avenits, Plavix generated $8.5 billion in sales last year. Defending...

2008-08-21 09:00:22

TOKYO and INDIANAPOLIS, Aug. 21 /PRNewswire-FirstCall/ -- A new, pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI 38 study showed patients who took prasugrel for acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI) and had survived their first cardiovascular event and then suffered a subsequent event, were 35 percent less likely to have a recurrent event (composite endpoint of heart attack, stroke...

2008-07-22 21:00:16

By Jeanine Kendle Plavix (clopidogrel) is a fairly well-known drug with considerable media coverage for cardiac conditions to prevent platelet (blood cell component) aggregation (sticking/clumping together). There is developing concerns regarding the use of Plavix and aspirin resistance, as well as a concern that up to 30 percent of patients do not respond to Plavix. These concerns have prompted researchers to continually look for better antiplatelet -- decrease blood cell...

2008-06-25 00:02:50

Eli Lilly and Co. says the U.S. Food and Drug Administration has extended the review period for the experimental blood thinner prasugrel. The drug, which would be marketed under the name Effient, will be up for review by the FDA in September, Eli Lilly said Monday. We remain confident in our prasugrel submission package, said Dr. Jennifer Stotka, vice president for Global Regulatory Affairs at Lilly. Prasugrel is being co-developed by Daiichi Sankyo Co. in Japan and Indianapolis-based Eli...

2008-06-24 09:03:23

Daiichi Sankyo Company and Eli Lilly and Company have said that the FDA has extended the review period for the prasugrel new drug application based on supplemental information provided during the review period. This three-month extension allows the FDA time to complete its review. The prasugrel new drug application was granted priority review by the FDA in February 2008. The new FDA action date for prasugrel is September 26, 2008. The proposed indication for prasugrel is for the...

2008-06-24 02:29:21

TOKYO and INDIANAPOLIS, June 23 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, and Eli Lilly and Company said that the U.S. Food and Drug Administration (FDA) has extended the review period for the prasugrel new drug application (NDA) based on supplemental information provided during the review period. This three month extension allows the FDA time to complete its review. The prasugrel NDA was granted priority review by the FDA in February 2008. The new FDA action date for...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related